May 16, 2023 / 03:00PM GMT
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good morning. I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets, and welcome again. Our next presenting company is Gilead. Really pleased to have with us their Chief Medical Officer, Merdad Parsey. Merdad, thank you again.
Merdad V. Parsey - Gilead Sciences, Inc. - Chief Medical Officer
Thanks. Thanks for having me.
Questions and Answers:
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology AnalystSo a lot to cover. So I want to kick it off. Maybe starting with the oncology portfolio and Trodelvy. You recently got approval for Trodelvy based on the TROPiCS -- the positive TROPiCS-02 data. And I guess I was wondering if you could tell us a little bit more about what you're seeing since the approval in terms of how Trodelvy is being incorporated into clinical practice, maybe both what you're seeing in terms of the more mature triple-negative area as well as
Trustpilot
